Hirokazu Taniguchi

List of Publications by Year
in descending order

42 papers	1,016 citations	516561 16 h-index	454834 30 g-index
43 all docs	43 docs citations	43 times ranked	1449 citing authors

#	Article	IF	Citations
1	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nature Communications, 2019, 10, 259.	5.8	223
2	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer Research, 2019, 79, 1658-1670.	0.4	79
3	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2244-2256.	3.2	75
4	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature Communications, 2020, 11, 4607.	5.8	69
5	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discovery, 2021, 11, 3028-3047.	7.7	66
6	Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 741.	1.3	65
7	WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Reports, 2022, 39, 110814.	2.9	43
8	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. Molecular Cancer Therapeutics, 2018, 17, 17-25.	1.9	37
9	Remarkable response of nivolumabâ€refractory lung cancer to salvage chemotherapy. Thoracic Cancer, 2018, 9, 175-180.	0.8	34
10	Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup. Gut, 2021, 70, 1469-1478.	6.1	30
11	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinibâ€resistance of <scp>EML</scp>4â€<scp>ALK</scp> lung cancer and circumvention by epidermal growth factor receptor inhibitors. Cancer Science, 2017, 108, 53-60.	1.7	28
12	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Journal of Hematology and Oncology, 2021, 14, 170.	6.9	26
13	Dynamics of blood neutrophilâ€related indices during nivolumab treatment may be associated with response to salvage chemotherapy for nonâ€small cell lung cancer: A hypothesisâ€generating study. Thoracic Cancer, 2019, 10, 341-346.	0.8	25
14	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged LungÂCancer. Journal of Thoracic Oncology, 2020, 15, 752-765.	0.5	24
15	Impact of <scp>MET</scp> inhibition on smallâ€cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/<scp>MET</scp> pathway. Cancer Science, 2017, 108, 1378-1385.	1.7	20
16	Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum. Internal Medicine, 2017, 56, 979-982.	0.3	18
17	Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy. Cancer Research, 2022, 82, 472-483.	0.4	18
18	Small molecule inhibitor of HSP47 prevents pro-fibrotic mechanisms of fibroblasts inÂvitro. Biochemical and Biophysical Research Communications, 2020, 530, 561-565.	1.0	17

#	Article	IF	Citations
19	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular Cancer Therapeutics, 2019, 18, 947-956.	1.9	14
20	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. Npj Precision Oncology, 2022, 6, 5.	2.3	13
21	Remarkable response to pembrolizumab with platinumâ€doublet in PDâ€L1â€low pulmonary sarcomatoid carcinoma: A case report. Thoracic Cancer, 2021, 12, 1126-1130.	0.8	11
22	Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. Thoracic Cancer, 2018, 9, 1522-1524.	0.8	9
23	Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient. Thoracic Cancer, 2017, 8, 706-709.	0.8	8
24	Presence of few PDâ€1â€expressing tumorâ€infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for nonâ€small cell lung cancer: An exploratory case series. Thoracic Cancer, 2018, 9, 1305-1311.	0.8	7
25	Cooperative participation of epigenomic and genomic alterations in the clinicopathological diversity of gastric adenocarcinomas: significance of cell adhesion and epithelialâ€“mesenchymal transition-related signaling pathways. Carcinogenesis, 2020, 41, 1473-1484.	1.3	7
26	Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab. Respirology Case Reports, 2013, 1, 14-16.	0.3	5
27	Phase <scp>I</scp> study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced nonâ€squamous nonâ€small cell lung cancer. Thoracic Cancer, 2017, 8, 577-581.	0.8	5
28	Risk for lymph node metastasis in Epsteinâ€“Barr virusâ€associated gastric carcinoma with submucosal invasion. Digestive Endoscopy, 2021, 33, 592-597.	1.3	5
29	A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 497-502.	1.1	4
30	Presence of heat shock protein 47-positive fibroblasts in cancer stroma is associated with increased risk of postoperative recurrence in patients with lung cancer. Respiratory Research, 2020, 21, 234.	1.4	4
31	Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase <scp>II</scp> study. Thoracic Cancer, 2020, 11, 1972-1978.	0.8	4
32	Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor. Journal of Clinical Medicine, 2021, 10, 4221.	1.0	4
33	Phase II study of nedaplatin and amrubicin as firstâ€line treatment for advanced squamous cell lung cancer. Thoracic Cancer, 2019, 10, 1764-1769.	0.8	3
34	Phase II study of ramucirumab and docetaxel for previously treated nonâ€small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. Thoracic Cancer, 2020, 11, 389-393.	0.8	3
35	Dabrafenib and trametinib therapy in an elderly patient with nonâ€small cell lung cancer harboring the BRAF V600E mutation. Thoracic Cancer, 2021, 12, 272-276.	0.8	3
36	In vivo imaging xenograft models for the evaluation of antiâ€brain tumor efficacy of targeted drugs. Cancer Medicine, 2017, 6, 2972-2983.	1.3	2

#	Article	IF	Citations
37	Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 1059-1064.	1.1	2
38	Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring. Journal of Clinical Medicine, 2020, 9, 1045.	1.0	2
39	Secondary EML4â€“ALK-positive Lung Adenocarcinoma in a Patient Previously Treated for Acute Lymphoblastic Leukemia in Childhood: A Case Report. Japanese Journal of Clinical Oncology, 2014, 44, 593-596.	0.6	1
40	Changes in Immunohistochemical Protein Levels in Anaplastic Lymphoma Kinase-positive Lung Adenocarcinoma Possibly due to Chemo-radiotherapy. Internal Medicine, 2016, 55, 1775-1778.	0.3	1
41	Efficacy of Sâ€1 after pemetrexed in patients with nonâ€small cell lung cancer: A retrospective multiâ€institutional analysis. Thoracic Cancer, 2021, 12, 2300-2306.	0.8	1
42	Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limitedâ€disease small cell lung cancer: protocol of <scp>ACIST</scp> study. Thoracic Cancer, 0, , .	0.8	1